ASX - By Stock
|
MSB |
Re:
ODAC August 2020 event materials
|
|
bretto32
|
85 |
25K |
9 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
85
|
25K
|
9
|
|
ASX - By Stock
|
ICI |
Re:
Ann: Response to Media Speculation
|
|
bretto32
|
43 |
15K |
2 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
43
|
15K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
post approval sp guesstimate
|
|
bretto32
|
168 |
54K |
4 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
168
|
54K
|
4
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Investor Presentation - NYC Nasdaq Event
|
|
bretto32
|
3 |
3.3K |
1 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
3
|
3.3K
|
1
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Commercial Update SCENESSE
|
|
bretto32
|
13 |
7.7K |
0 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
13
|
7.7K
|
0
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Commercial Update SCENESSE
|
|
bretto32
|
13 |
7.7K |
6 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
13
|
7.7K
|
6
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Commercial Update SCENESSE
|
|
bretto32
|
13 |
7.7K |
0 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
13
|
7.7K
|
0
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
bretto32
|
42 |
17K |
2 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
42
|
17K
|
2
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
bretto32
|
42 |
17K |
1 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
42
|
17K
|
1
|
|
ASX - By Stock
|
CUV |
Re:
Ann: afamelanotide Reduces DNA Photodamage in XP
|
|
bretto32
|
14 |
6.7K |
2 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
14
|
6.7K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
bretto32
|
914 |
286K |
26 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
914
|
286K
|
26
|
|
ASX - By Stock
|
CUV |
Re:
Cash Flows are deceiving
|
|
bretto32
|
7 |
4.0K |
5 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
7
|
4.0K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bretto32
|
32 |
12K |
6 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
32
|
12K
|
6
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bretto32
|
32 |
12K |
3 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
32
|
12K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
bretto32
|
914 |
286K |
4 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
914
|
286K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
bretto32
|
914 |
286K |
8 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
914
|
286K
|
8
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bretto32
|
32 |
12K |
5 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
32
|
12K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bretto32
|
32 |
12K |
1 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
32
|
12K
|
1
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Presentation - Jefferies London Healthcare Conference
|
|
bretto32
|
15 |
8.3K |
3 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
15
|
8.3K
|
3
|
|
ASX - By Stock
|
ICI |
Re:
Ann: Proposed issue of securities - ICI
|
|
bretto32
|
8 |
1.8K |
3 |
22/11/22 |
22/11/22 |
ASX - By Stock
|
8
|
1.8K
|
3
|
|
Charts
|
MSB |
Re:
MSB - Chart
|
|
bretto32
|
248 |
104K |
1 |
10/10/22 |
10/10/22 |
Charts
|
248
|
104K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
bretto32
|
4.7K |
1.0M |
3 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
4.7K
|
1.0M
|
3
|
|
ASX - By Stock
|
CUV |
Re:
Clinuvel compared to Imugene
|
|
bretto32
|
64 |
39K |
5 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
64
|
39K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Mortality Reduced by 75%
|
|
bretto32
|
64 |
18K |
3 |
05/05/21 |
05/05/21 |
ASX - By Stock
|
64
|
18K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Mortality Reduced by 75%
|
|
bretto32
|
64 |
18K |
7 |
05/05/21 |
05/05/21 |
ASX - By Stock
|
64
|
18K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
bretto32
|
1.6K |
460K |
1 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
460K
|
1
|
|
ASX - By Stock
|
CUV |
Re:
Shorts - general info
|
|
bretto32
|
748 |
287K |
4 |
22/03/21 |
22/03/21 |
ASX - By Stock
|
748
|
287K
|
4
|
|
ASX - By Stock
|
CUV |
Re:
Shorts - general info
|
|
bretto32
|
748 |
287K |
5 |
22/03/21 |
22/03/21 |
ASX - By Stock
|
748
|
287K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
Shorts - general info
|
|
bretto32
|
748 |
287K |
1 |
19/03/21 |
19/03/21 |
ASX - By Stock
|
748
|
287K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
bretto32
|
1.0K |
515K |
6 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
bretto32
|
796 |
393K |
7 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
7
|
|
ASX - By Stock
|
MSB Medicine |
Re:
Mesoblast $200 is possible
|
|
bretto32
|
71 |
58K |
2 |
20/09/20 |
20/09/20 |
ASX - By Stock
|
71
|
58K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MESO action tonight
|
|
bretto32
|
3.1K |
1.4M |
0 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
3.1K
|
1.4M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial
|
|
bretto32
|
299 |
138K |
16 |
04/09/20 |
04/09/20 |
ASX - By Stock
|
299
|
138K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
bretto32
|
576 |
230K |
2 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
576
|
230K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
bretto32
|
576 |
230K |
5 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
576
|
230K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Annual Financial Results Presentation
|
|
bretto32
|
97 |
42K |
13 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
97
|
42K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
bretto32
|
425 |
188K |
59 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
425
|
188K
|
59
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
bretto32
|
425 |
188K |
16 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
425
|
188K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Chances of Covid Trial being a success
|
|
bretto32
|
101 |
56K |
22 |
23/08/20 |
23/08/20 |
ASX - By Stock
|
101
|
56K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
bretto32
|
54 |
20K |
8 |
22/08/20 |
22/08/20 |
ASX - By Stock
|
54
|
20K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MESOBLAST- FUNDAMENTALS discussions
|
|
bretto32
|
305 |
114K |
9 |
22/08/20 |
22/08/20 |
ASX - By Stock
|
305
|
114K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
bretto32
|
54 |
20K |
3 |
21/08/20 |
21/08/20 |
ASX - By Stock
|
54
|
20K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
friends covid update
|
|
bretto32
|
201 |
76K |
3 |
20/08/20 |
20/08/20 |
ASX - By Stock
|
201
|
76K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
friends covid update
|
|
bretto32
|
201 |
76K |
6 |
19/08/20 |
19/08/20 |
ASX - By Stock
|
201
|
76K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
INVESTIGATION ALERT
|
|
bretto32
|
11 |
2.7K |
9 |
19/08/20 |
19/08/20 |
ASX - By Stock
|
11
|
2.7K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
friends covid update
|
|
bretto32
|
201 |
76K |
14 |
19/08/20 |
19/08/20 |
ASX - By Stock
|
201
|
76K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
friends covid update
|
|
bretto32
|
201 |
76K |
3 |
19/08/20 |
19/08/20 |
ASX - By Stock
|
201
|
76K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
bretto32
|
17K |
6.6M |
14 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
17K
|
6.6M
|
14
|
|
ASX - By Stock
|
MSB |
Re:
FDA approval chances and time frame
|
|
bretto32
|
18 |
8.8K |
26 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
18
|
8.8K
|
26
|
|